| P50 | author | Thomas Lindenstrøm | Q56884096 |
| | Else Marie Agger | Q111279894 |
| | Peter Andersen | Q54029065 |
| P2093 | author name string | Claus Aagaard | |
| | Jon Hansen | |
| | Julie Lindberg-Levin | |
| P2860 | cites work | Protective anti-mycobacterial T cell responses through exquisitein vivo activation of vaccine-targeted dendritic cells | Q58827812 |
| | Interleukin-10 and the interleukin-10 receptor | Q24290912 |
| | T helper 17 cells promote cytotoxic T cell activation in tumor immunity | Q24646584 |
| | Type, density, and location of immune cells within human colorectal tumors predict clinical outcome | Q28131662 |
| | Transforming growth factor-beta regulation of immune responses | Q28303115 |
| | Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity | Q28749845 |
| | The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes | Q33273936 |
| | Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. | Q33350210 |
| | Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements | Q33367582 |
| | A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells | Q33459148 |
| | Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice | Q33609436 |
| | Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer | Q33932032 |
| | Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate | Q34099417 |
| | Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer | Q34210036 |
| | Vaccine adjuvants: current state and future trends | Q34358206 |
| | Therapeutic cancer vaccines: are we there yet? | Q34786691 |
| | Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation | Q34920323 |
| | The critical role of type-1 innate and acquired immunity in tumor immunotherapy | Q35911850 |
| | Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines | Q36576750 |
| | Type I interferon as a stimulus for cross-priming | Q37027815 |
| | Therapeutic cancer vaccines in combination with conventional therapy | Q37771267 |
| | Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model | Q37856989 |
| | Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method | Q39812855 |
| | Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies | Q39828440 |
| | Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis | Q40207805 |
| | Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma | Q40207813 |
| | Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses | Q41626628 |
| | Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen | Q43252469 |
| | Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01. | Q44398270 |
| | Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection | Q44467383 |
| | Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma | Q45287769 |
| | Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia | Q46065889 |
| | Intraperitoneal immunization of human subjects with tetanus toxoid induces specific antibody-secreting cells in the peritoneal cavity and in the circulation, but fails to elicit a secretory IgA response | Q46443265 |
| P433 | issue | 6 | |
| P304 | page(s) | 893-903 | |
| P577 | publication date | 2011-11-18 | |
| P1433 | published in | Cancer Immunology, Immunotherapy | Q5031409 |
| P1476 | title | CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice | |
| P478 | volume | 61 | |